A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.

Related documents

• An ICF-informed comparison of fine motor assessment measures.#663336
• Subclinical cardiovascular risk among adolescents with HIV in Tanzania: the role of sleep behaviour and antiretroviral regimen on arterial stiffness.#663335
• Effects of transcutaneous cervical vagus nerve stimulation on autonomic function in posttraumatic stress disorder and opioid use disorder.#663334